Physician profile
Walid Abou Assi
NPI 1003867433
$886.82
in general payments reported to CMS, 2019-2025
12 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.58 · 2020: $149 · 2021: $96.84 · 2022: $25.25 · 2023: $95.97 · 2024: $197 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.22 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.94 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $163.58 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $77.89 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $65.58 | 2025 | Vowst, Zenpep |
| Astrazeneca Pharmaceuticals LP | $52.08 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $45.26 | 2020-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $40.38 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.46 | 2025 | |
| Scpharmaceuticals INC. | $29.81 | 2025 | |
| Welch Allyn | $20.50 | 2021 | |
| Horizon Therapeutics Plc | $17.17 | 2021 | |
| Glaxosmithkline, LLC. | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Abou Assi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.